Hydrazine-mediated carbonyl-alkyne/allene reductive olefination.

Linjun Qi, Wencan Wang, Lijin Zhou, Zhi-Xiang Yu, Xiaofeng Tong

Abstract read

In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Linjun QiSchool of Pharmaceutical and Chemical Engineering, Zhejiang Key Laboratory of New Drug Development for Central Nervous System Diseases, Taizhou University, Taizhou, Zhejiang, China. qilinjun@tzc.edu.cn.

Wencan WangBeijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, China.

Lijin ZhouSchool of Pharmaceutical and Chemical Engineering, Zhejiang Key Laboratory of New Drug Development for Central Nervous System Diseases, Taizhou University, Taizhou, Zhejiang, China.ORCID http://orcid.org/0009-0003-2694-2346

Zhi-Xiang YuBeijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molecular Engineering, Peking University, Beijing, China. yuzx@pku.edu.cn.ORCID http://orcid.org/0000-0003-0939-9727

Xiaofeng TongSchool of Pharmaceutical and Chemical Engineering, Zhejiang Key Laboratory of New Drug Development for Central Nervous System Diseases, Taizhou University, Taizhou, Zhejiang, China. xftong@tzc.edu.cn.ORCID http://orcid.org/0000-0002-6789-1691

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cycloolefin is a privileged motif with significant implications across multiple disciplines. While cycloolefination represents the most unified disconnection strategy, the corresponding approaches are notably scarce. Here we report a hydrazine-mediated carbonyl-alkyne reductive olefination (CARO), offering a minimalist approach to structurally complex cycloolefins. This CARO protocol is also applicable to carbonyl-allene and lactol-alkyne analogues. Experimental studies and DFT calculations suggest that the CARO follows a domino mechanism involving carbonyl-hydrazine condensation, ene reaction of free hydrazone, and denitrogenative retro-ene reaction. Its synthetic potential is demonstrated by the facile preparation of several medicinally important molecules, deuterated compounds and valuable chirons. This study provides a fundamentally distinct, operationally simple and cost-effective strategy for accessing complex architectures, appealing to both organic and medicinal chemists.

Identifiers

PMID42173873

DOI10.1038/s41467-026-73510-5

PMCPMC13385400

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.